(A) RPS19, C3b/iC3b, Anexin V, CD11b, and C5aR1 in murine tumors
generated in FVB/N Her2/neu transgenic mouse by injecting NT-5 cells. Arrows:
accumulation of CD11b+ cells (upper middle) and
co-localization of RPS19 with C5aR1 (lowest panel), scale bars 5 μm
except upper middle panel which is 25 μm. (B-i, ii)
Immunoprecipitation of RPS19-C5aR1 complex from whole cell lysate (Tum. Lys.) of
NT-5 tumors from Her2/neu transgenic mouse. Murine macrophages RAW 264.7 (Mac)
were used a positive control for C5aR1 expression and recombinant RPS19 (rRP
S19) as control for RPS19. (iii) Quantification of data from ii,
*P=0.0364 (right) and
*P=0.003 (left) by One-Way-ANOVA. FACS
analysis of (C) RPS19 on the surface of monocytic
(Gr-1int) vs. granulocytic (Gr-1high) MDSC and
(D) C5aR1 expression on monocytic vs. granulocytic MDSC. Black
lines: RPS19 and C5aR1 antibodies. Grey lines: isotype controls.
(E) Pre- and post-sort FACS of spleen MDSC from NT-5 tumor-bearing
mice. Biding of fluorescently labeled-RPS19 or C5a in the absence (continuous
black lines) or presence (dashed lines) of C5aR1 antagonist (C5aRA) to
(F) sorted MDSC, P<0.0001-RPS19,
P=0.0001-C5a by One-Way ANOVA or (G)
murine macrophages, P<0.0001-RPS19 and C5a by One-Way ANOVA.
(H) Chemotaxis assay; y-axis number of murine macrophages (RAW
264.7) in lower chamber at the end of experiment,
*P<0.0001 by One-Way ANOVA. Data are representative
of one experiment with n=5 for A, three independent experiments for
B–G, and four replicates for H.